Uterine fibroids: an update on current and emerging medical treatment options

References

• SuttonCHysterectomy: a historical perspectiveBaillieres Clin Obstet Gynaecol19971111229155933
   PubMed Web of Science ®Google Scholar
• MaheuxRTreatment of uterine leiomyomata: past, present and futureGenazzaniARPetragliaFVolpeGProgress in Gynecology and ObstetricsCarnforthParthenon Publishing Group1990173190
   Google Scholar
• SemmKNew methods of pelviscopy (gynecologic laparoscopy) for myomectomy, ovariectomy, tubectomy and adnectomyEndoscopy197911028593156118
   PubMed Web of Science ®Google Scholar
• GordonAGMagosALThe development of laparoscopic surgeryBaillieres Clin Obstet Gynaecol198933429449
   PubMed Web of Science ®Google Scholar
• SteinerRAWightETadirYHallerUElectrical cutting device for laparoscopic removal of tissue from the abdominal cavityObstet Gynecol1993814714748437807
   PubMed Web of Science ®Google Scholar
• della BadiaCKariniHEndometrial stromal sarcoma diagnosed after uterine morcellation in laparoscopic supracervical hysterectomyJ Minim Invasive Gynecol201017679179320955991
   PubMed Web of Science ®Google Scholar
• AnupamaRAhmadSZKuriakoseSVijaykumarDKPavithranKSeethalekshmyNVDisseminated peritoneal leiomyosarcomas after laparoscopic “myomectomy” and morcellationJ Minim Invasive Gynecol201118338638921545964
   PubMed Web of Science ®Google Scholar
• CohenSLEinarssonJIWangKCContained power morcellation within an insufflated isolation bagObstet Gynecol2014124349149725162248
   PubMed Web of Science ®Google Scholar
• YangHXcLYaoCProportion of uterine malignant tumors in patients with laparoscopic myomectomy: a national multicenter study in ChinaChin Med J20171302661266529133752
   PubMed Web of Science ®Google Scholar
• WongMde WildeRLIsaacsonKReducing the spread of occult uterine sarcoma at the time of minimally invasive gynecologic surgeryArch Gynecol Obstet2018297228529329128980
   PubMed Web of Science ®Google Scholar
• SiedhoffMTCohenSLTissue extraction techniques for leiomyomas and uteri during minimally invasive surgeryObstet Gynecol201713061251126029112659
   PubMed Web of Science ®Google Scholar
• RavinaJHHerbreteauDCiraru-VigneronNArterial embolisation to treat uterine myomataLancet199534689766716727544859
   PubMed Web of Science ®Google Scholar
• HutchinsFLJrWorthington-KirschRBerkowitzRPSelective uterine artery embolization as primary treatment for symptomatic leiomyomata uteriJ Am Assoc Gynecol Laparosc19996327928410459027
   PubMedGoogle Scholar
• SpiesJBCurrent role of uterine artery embolization in the management of uterine fibroidsClin Obstet Gynecol20165919310226630074
   PubMed Web of Science ®Google Scholar
• JenneJWPreusserTGüntherMHigh-intensity focused ultrasound: principles, therapy guidance, simulations and applicationsZeitschrift für Medizinische Physik201222431132222884198
   PubMed Web of Science ®Google Scholar
• BrownMRDFarquhar-SmithPWilliamsJETer HaarGDesouzaNMThe use of high-intensity focused ultrasound as a novel treatment for painful conditions – a description and narrative review of the literatureBr J Anaesth2015115452053026385662
   PubMed Web of Science ®Google Scholar
• SheWHCheungTTJenkinsCRIrwinMGClinical applications of high-intensity focused ultrasoundHong Kong Med J20162238239227380753
   PubMed Web of Science ®Google Scholar
• DonnezJDonnezODolmansM-MWith the advent of selective progesterone receptor modulators, what is the place of myoma surgery in current practice?Fertil Steril201410264064825106762
   PubMed Web of Science ®Google Scholar
• SinghSSBellandLContemporary management of uterine fibroids: focus on emerging medical treatmentsCurr Med Res Opin2015311112
   PubMed Web of Science ®Google Scholar
• GurusamyKSVaughanJFraserISBestLMJRichardsTMedical therapies for uterine fibroids-a systematic review and network meta-analysis of randomised controlled trialsPLoS One2016112e0149631art26919185
   PubMed Web of Science ®Google Scholar
• BartelsCBCaytonKCChuongFSAn evidence-based approach to the medical management of fibroids: a systematic reviewClin Obstet Gynecol2016591305226756261
   PubMed Web of Science ®Google Scholar
• GoodmanALProgesterone therapy in uterine fibromaJ Clin Endocrinol Metab19466540240820983484
   PubMed Web of Science ®Google Scholar
• SegaloffAWeedJCSternbergWHThe progesterone therapy of human uterine leiomyomasEndocrinol Metab194991212731291
   Web of Science ®Google Scholar
• GoldzieherJWMaqueoMRicaudLAguilarJACanalesEInduction of degenerative changes in uterine myomas by high-dosage progestin therapyAm J Obstet Gynecol1966968107810875928464
   PubMed Web of Science ®Google Scholar
• FarquharCArrollBEkeromaAThe Working Party of the New Zealand Guidelines Group. An evidence-based guideline for the management of uterine fibroidsAust N Z J Obstet Gynaecol20014112514011453261
   PubMed Web of Science ®Google Scholar
• LefebvreGVilosGAllaireCJeffreyJThe management of uterine leiomyomasJ Obstet Gynaecol Can20032539640512738981
   PubMedGoogle Scholar
• NakaiGYamadaTHamadaTPathological findings of uterine tumors preoperatively diagnosed as red degeneration of leiomyoma by MRIAbdom Radiol201742718251831
   PubMed Web of Science ®Google Scholar
• HachiyaKKatoHKawaguchiSRed degeneration of a uterine fibroid following the administration of gonadotropin releasing hormone agonistsJ Obstet Gynaecol20163681018101927750451
   PubMedGoogle Scholar
• XuQOharaNLiuJProgesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cellsMol Hum Reprod200814318119118216291
   PubMed Web of Science ®Google Scholar
• RossRKPikeMCVesseyMPBullDYeatesDCasagrandeJTRisk factors for uterine fibroids: reduced risk associated with oral contraceptivesBr Med J198629365433593623730804
   PubMed Web of Science ®Google Scholar
• ParazziniFLa VecchiaCNegriECecchettiGFedeleLEpidemiological characteristics of women with uterine fibroids: a case-control studyObstet Gynecol1988728538573186092
   PubMed Web of Science ®Google Scholar
• SamadiARLeeNCFlandersWDBoringJR3rdParrisEBRisk factors for self-reported uterine fibroids: a case-control studyAm J Public Health19966858862
   Web of Science ®Google Scholar
• FriedmanAJThomasPPDoes low-dose combination oral contraceptive use affect uterine size or menstrual flow in premenopausal women with leiomyomas?Obstet Gynecol19958546316357898846
   PubMed Web of Science ®Google Scholar
• PitkinRMDoes low-dose combination oral contraceptive use affect uterine size or menstrual flow in premenopausal women with leiomyomas [Retraction of Friedman and Thomas]Obstet Gynecol1995867287566837
   PubMed Web of Science ®Google Scholar
• OrtmannOWeissJMDiedrichKGonadotrophin-releasing hormone (GnRH) and GnRH agonists: mechanisms of actionReprod Biomed Online20025Suppl 11712537774
   PubMedGoogle Scholar
• FilicoriMHallDALoughlinJSRivierJValeWCrowleyWFJrA conservative approach to the management of uterine leiomyoma: pituitary desensitization by a luteinizing hormone-releasing hormone analogueAm J Obstet Gynecol198314767267276356927
   PubMed Web of Science ®Google Scholar
• MattaWHMShawRWNyeMLong-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelinBr J Obstet Gynaecol19899622002062495020
   PubMedGoogle Scholar
• LetteriGSShawkerTHCoddingtonCCShawkerTHLoriauxDLCollinsRLEfficacy of gonadotropin releasing hormone agonist in the treatment of uterine leiomyomata: long-term follow-upFertil Steril1989519519562498132
   PubMed Web of Science ®Google Scholar
• BenagianoGUterine fibroids: literature review and summary of postersHorm Res198932Suppl 11201242693322
   PubMedGoogle Scholar
• RouxCPelissierCListratVBone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitoninOsteoporos Int1995531851907655179
   PubMed Web of Science ®Google Scholar
• ChengY-MChouC-YHuangS-CLinH-COestrogen deficiency causes DNA damage in uterine leiomyoma cells: a possible mechanism for shrinkage of fibroids by GnRH agonistsBr J Obstet Gynaecol200110895102
   Google Scholar
• LumsdenMAWestCPBairdDTGoserelin therapy before surgery for uterine fibroidsLancet198732985233637
   Google Scholar
• LethabyAVollenhovenBSowterMEfficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic reviewBr J Obstet Gynaecol20021091010971108
   Google Scholar
• StovallTGLingFWHenryLCWoodruffMRA randomized trial evaluating leuprolide acetate before hysterectomy as treatment for leiomyomasAm J Obstet Gynecol19911646142014251904681
   PubMed Web of Science ®Google Scholar
• CandianiGBVercelliniPFedeleLUse of goserelin depot, a gonadotropin releasing hormone agonist, for the treatment of menorrhagia and severe anemia in women with leiomyomata uteriActa Obstet Gynecol Scand19906954134152148663
   PubMed Web of Science ®Google Scholar
• BenagianoGCronjéHKivinenSTZoladex (goserelin acetate) and the anemic patient: results of a multicenter fibroid studyFertil Steril1996662232298690106
   PubMed Web of Science ®Google Scholar
• BenagianoGMoriniAPrimieroFMFibroids: overview of current and future treatment optionsBr J Obstet Gynaecol199299s71822
   PubMedGoogle Scholar
• NedwichAFruminAMeranzeDRErythrocytosis associated with uterine myomasAm J Obstet Gynecol196284217417814478738
   PubMed Web of Science ®Google Scholar
• LevgurMDlevieMThe myomatous erythrocytosis syndrome: a reviewObstet Gynecol1995866102610307501327
   PubMed Web of Science ®Google Scholar
• MattaWHMStabileIShawRWCampbellSDoppler assessment of uterine blood flow changes in patients with fibroids receiving the gonadotropin releasing hormone agonist buserelinFertil Steril198849108310852967195
   PubMed Web of Science ®Google Scholar
• FriedmanAJReinMSHarrison-AtlasDA randomized, placebo-controlled, double-blind study evaluating leuprolide acetate depot treatment before myomectomyFertil Steril1989527287332509250
   PubMed Web of Science ®Google Scholar
• MettlerLSemmKLaparoscopic approach of fibroid excision after treatment with GnRH analoguesLunenfeldBCarnforthIVProceedings of the IIIrd International Symposium on GnRH Analogues in Cancer and Human ReproductionUKParthenon Publ, London19939598
   Google Scholar
• MettlerLAlvarez-RodasESemmKHormonal treatment and pelviscopic myomectomyDiagn Ther Endosc19951421722118493368
   PubMedGoogle Scholar
• DodirotVDubuissonJ-BChapronCRecurrence of leiomyomata after laparoscopic myomectomyJ Am Assoc Gynecol Laparosc2001849550011677326
   PubMedGoogle Scholar
• FedeleLVercelliniPBianchiSBrioschiDDortaMTreatment with GnRH agonists before myomectomy and the risk of short-term myoma recurrenceBr J Obstet Gynaecol19909753933962115379
   PubMedGoogle Scholar
• FriedmanAJDalyMJuneau-NorcrossMRecurrence of myomas after myomectomy in women pretreated with leuprolide acetate depot or placeboFertil Steril1992582052081624009
   PubMed Web of Science ®Google Scholar
• DonnezJSchrursBGillerotSSandowJClerckxFTreatment of uterine fibroids with implants of gonadotropin-releasing hormone agonist: assessment by hysterographyFertil Steril19895169479502498131
   PubMed Web of Science ®Google Scholar
• DonnezJNisolleMGrandjeanPGillerotSClerckxFThe place of GnRH agonists in the treatment of endometriosis and fibroids by advanced endoscopic techniquesBr J Obstet Gynaecol199299Suppl 731331532508
   PubMedGoogle Scholar
• SeracchioliRVenturoliSColomboFMGnRH agonist treatment before total laparoscopic hysterectomy for large uteriJ Am Assoc Gynecol Laparosc200310331631914567804
   PubMedGoogle Scholar
• WestCPLumsdenMAHillierHSweetingVBairdDTPotential role for medroxyprogesterone acetate as an adjunct to goserelin (Zoladex) in the medical management of uterine fibroidsHum Reprod1992733283321534089
   PubMed Web of Science ®Google Scholar
• CarrBRMarshburnPBWeatherallPTAn evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trialJ Clin Endocrinol Metab199376121712238496313
   PubMed Web of Science ®Google Scholar
• PalombaSOrioFJrRussoTLong-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomasHum Reprod20041961308131415117890
   PubMed Web of Science ®Google Scholar
• PalombaSOrioFJrMorelliMRaloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: effects on bone metabolismJ Clin Endocr Metab200287104476448112364422
   PubMed Web of Science ®Google Scholar
• BroekmansFJHompesPGAHeitbrinkMATwo-step gonadotropin-releasing hormone agonist treatment of uterine leiomyomas: standard-dose therapy followed by reduced-dose therapyAm J Obstet Gynecol19961755120812168942490
   PubMed Web of Science ®Google Scholar
• BarbieriRLGonadotropin-releasing hormone agonists and estrogen-progestogen replacement therapyAm J Obstet Gynecol199016225935952137979
   PubMed Web of Science ®Google Scholar
• FriedmanAJTreatment of leiomyomata uteri with short-term leuprolide followed by leuprolide plus estrogen–progestin hormone replacement therapy for 2 years: a pilot studyFertil Steril19895135265282537769
   PubMed Web of Science ®Google Scholar
• MclarenJSMorrisERymerJGonadotrophin receptor hormone analogues in combination with add-back therapy: an updateMenopause Int2012182687222611225
   PubMedGoogle Scholar
• MoroniRMMartinsWPFerrianiRAAdd-back therapy with GnRH analogues for uterine fibroidsCochrane Database Syst Rev201520CD010854
   Google Scholar
• BenagianoGMoriniAAleandriVSequential Gn-RH super-agonist and medroxyprogesterone acetate treatment of uterine leiomyomataInt J Obstet Gynecol1990334333343
   PubMed Web of Science ®Google Scholar
• LeoDVMorganteGLanzettaDDanazol administration after gonadotropin-releasing hormone analogue reduces rebound of uterine myomasHum Reprod1997123573609070725
   PubMed Web of Science ®Google Scholar
• KettelLMMurphyAAMoralesAJRivierJValeWYenSSRapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonistFertil Steril19936046426468405517
   PubMed Web of Science ®Google Scholar
• Gonzalez-BarcenaDAlvarezRBOchoaEPTreatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist CetrorelixHum Reprod1997129202820359363724
   PubMed Web of Science ®Google Scholar
• FelberbaumREGermerULudwigMTreatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist CetrorelixHum Reprod1998136166016689688409
   PubMed Web of Science ®Google Scholar
• FelberbaumRELudwigMDiedrichKMedical treatment of uterine fibroids with the LHRH antagonist: CetrorelixContracept Fertil Sex19992770170910605180
   PubMedGoogle Scholar
• EngelJBAudebertAFrydmanRZivnyJDiedrichKPresurgical short term treatment of uterine fibroids with different doses of cetrorelix acetate: a double-blind, placebo-controlled multicenter studyEur J Obstet Gynecol Reprod Biol2007134222523216930803
   PubMed Web of Science ®Google Scholar
• ChenWYoshidaSOharaNMatsuoHMorizaneMMaruoTGonadotropin-releasing hormone antagonist cetrorelix down-regulates proliferating cell nuclear antigen and epidermal growth factor expression and up-regulates apoptosis in association with enhanced poly(adenosine 5′-diphosphate-ribose) polymerase expression in cultured human leiomyoma cellsJ Clin Endocrinol Metab200590288489215536154
   PubMed Web of Science ®Google Scholar
• BrittenJLMalikMLevyGMendozaMCatherinoWHGonadotropin-releasing hormone (GnRH) agonist leuprolide acetate and GnRH antagonist cetrorelix acetate directly inhibit leiomyoma extracellular matrix productionFertil Steril20129851299130722901846
   PubMed Web of Science ®Google Scholar
• FliermanPAOberyéJJHulstVPde BlokSRapid reduction of leiomyoma volume during treatment with the GnRH antagonist ganirelixBJOG2005112563864215842290
   PubMed Web of Science ®Google Scholar
• BetzSFZhuY-FChenCStruthersRSNon-peptide gonadotropin-releasing hormone receptor antagonistsJ Med Chem200851123331334818419112
   PubMed Web of Science ®Google Scholar
• ZhuY-FGrossTDGuoZIdentification of 1-arylmethyl-3-(2-aminoethyl)-5-aryluracil as novel gonadotropin-releasing hormone receptor antagonistsJ Med Chem200346112023202612747774
   PubMed Web of Science ®Google Scholar
• GuoZZhuY-FGrossTDSynthesis and structure-activity relationships of 1-arylmethyl-5-aryl-6-methyluracils as potent gonadotropin-releasing hormone receptor antagonistsJ Med Chem20044751259127114971906
   PubMed Web of Science ®Google Scholar
• RowbottomMWTucciFCZhuY-FSynthesis and structure– activity relationships of (R)-1-alkyl-3-[2-(2-amino)phenethyl]-5-(2-fluorophenyl)-6-methyluracils as human GnRH receptor antagonistsBioorg Med Chem Lett20041492269227415081023
   PubMed Web of Science ®Google Scholar
• TucciFCZhuY-FStruthersRS3-[(2R)-Amino-2-phenylethyl]-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)-6-methylpyrim-idin-2,4-dione (NBI 42902) as a potent and orally active antagonist of the human gonadotropin-releasing hormone receptor. Design, synthesis, and in vitro and in vivo characterizationJ Med Chem20054841169117815715483
   PubMed Web of Science ®Google Scholar
• ZhaoLGuoZChenY5-Aryluracils as potent GnRH antagonists – characterization of atropisomersBioorg Med Chem Lett200818113344334918442905
   PubMed Web of Science ®Google Scholar
• ChenCChenYPontilloJPotent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activityBioorg Med Chem Lett200818113301330518442910
   PubMed Web of Science ®Google Scholar
• ReganCFGuoZChenYZwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical propertiesBioorg Med Chem Lett200818164503450718667310
   PubMed Web of Science ®Google Scholar
• ChenCWuDGuoZDiscovery of sodium R-(+)-4-{2-[5-(2-fluoro- 3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl -2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino} butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptorJ Med Chem200851237478748519006286
   PubMed Web of Science ®Google Scholar
• StruthersRSChenTCampbellBSuppression of serum luteinizing hormone in postmenopausal women by an orally administered nonpeptide antagonist of the gonadotropin-releasing hormone receptor (NBI-42902)J Clin Endocrinol Metab200691103903390716849403
   PubMed Web of Science ®Google Scholar
• StruthersRSXieQSullivanSKPharmacological characterization of a novel nonpeptide antagonist of the human gonadotropin-releasing hormone receptor, NBI-42902Endocrinology2007148285786717095587
   PubMed Web of Science ®Google Scholar
• StruthersRSNichollsAJGrundyJSuppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolixJ Clin Endocrinol Metab200994254555119033369
   PubMed Web of Science ®Google Scholar
• CarrBDmowskiWPO’BrienCElagolix, an oral GnRH antagonist, versus subcutaneous depot medroxy-progesterone acetate for the treatment of endometriosis: effects on bone mineral densityReprod Sci201421111341135125249568
   PubMed Web of Science ®Google Scholar
• EzzatiMCarrBRElagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related painWomens Health20151111928
   Google Scholar
• TaylorHSGiudiceLCLesseyBATreatment of endometriosis-associated pain with elagolix, an oral GnRH antagonistN Engl J Med20173771284028525302
   PubMed Web of Science ®Google Scholar
• SurreyETaylorHSGiudiceLLong-term outcomes of elagolix in women with endometriosis: results from two extension studiesObstet Gynecol2018132114716029889764
   PubMed Web of Science ®Google Scholar
• NgJChwaliszKCarterDCKleinCEDose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal womenJ Clin Endocrinol Metab201710251683169128323948
   PubMed Web of Science ®Google Scholar
• ArcherDFStewartEAJainRIElagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept studyFertil Steril2017108115216028579415
   PubMed Web of Science ®Google Scholar
• KimSMYooTLeeSYEffect of SKI2670, a novel, orally active, non-peptide GnRH antagonist, on hypothalamic–pituitary– gonadal axisLife Sci201513916617426321528
   PubMed Web of Science ®Google Scholar
• KimS-MLeeMLeeSYDiscovery of an orally bioavailable gonadotropin-releasing hormone receptor antagonistJ Med Chem201659199150917227608177
   PubMed Web of Science ®Google Scholar
• MiwaKHitakaTImadaTDiscovery of 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl] phenyl}-3-methoxyurea (TAK-385) as a potent, orally active, non-peptide antagonist of the human gonadotropin-releasing hormone receptorJ Med Chem201154144998501221657270
   PubMed Web of Science ®Google Scholar
• NakataDMasakiTTanakaASuppression of the hypothalamic– pituitary–gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in miceEur J Pharmacol201472316717424333551
   PubMed Web of Science ®Google Scholar
• PohlOMarchandLFawkesNGottelandJ-PLoumayeEGonadotropin-releasing hormone receptor antagonist mono- and combination therapy with estradiol/norethindrone acetate add-back: pharmacodynamics and safety of OBE2109J Clin Endocrinol Metab2018103249750429216361
   PubMed Web of Science ®Google Scholar
• ZaloudekCNorrisHJKurmanRGBlaustein’s Pathology of the Female Genital Tract5th edNew YorkSpringer-Verlag2002373408
   Google Scholar
• FriedmanAJBarbieriRLDoubiletPMA randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteriFertil Steril1988494044092963759
   PubMed Web of Science ®Google Scholar
• KawaguchiKFujiiSKonishiIMitotic activity in uterine leiomyomas during the menstrual cycleAm J Obstet Gynecol198916036376412929683
   PubMed Web of Science ®Google Scholar
• MaruoTMatsuoHShimomuraYEffects of progesterone on growth factor expression in human uterine leiomyomaSteroids20036810–1381782414667973
   PubMed Web of Science ®Google Scholar
• SmithSKThe regulation of fibroid growth: time for a re-think?Br J Obstet Gynaecol1993100119779788251467
   PubMedGoogle Scholar
• WagenfeldASaundersPTKWhitakerLCritchleyHODSelective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapiesExpert Opin Ther Targets20162091045105427138351
   PubMed Web of Science ®Google Scholar
• Contraception and Reproductive Health BranchNICHD Report2004 Available from: https://www.nichd.nih.gov/publications/pubs/council_crhb_2004/indexAccessed October 18, 2018
   Google Scholar
• HerrmannWWyssRRiondelAThe effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancyC R Seances Acad Sci III1982294189339386814714
   PubMedGoogle Scholar
• MurphyAAKettelLMMoralesAJRobertsVJYenSSRegression of uterine leiomyomata in response to the antiprogesterone RU 486J Clin Endocrinol Metab19937625135178432797
   PubMed Web of Science ®Google Scholar
• YenSSCClinical use of RU 486 in the treatment of uterine fibroidsDonaldsonMSDorflingerLBrownSSBenetLSClinical Applications of Mifepristone (RU 486) and Other AntiprogestinsWashington, DCNational Academy Press1993189209
   Google Scholar
• ReinschRCMurphyAAMoralesAJYenSSThe effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized studyAm J Obstet Gynecol19941706162316288203418
   PubMed Web of Science ®Google Scholar
• SteinauerJPrittsEAJacksonRJacobyAFSystematic review of mifepristone for the treatment of uterine leiomyomataObstet Gynecol200410361331133615172874
   PubMed Web of Science ®Google Scholar
• FiscellaKEisingerSHMeldrumSFengCFisherSGGuzickDSEffect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trialObstet Gynecol200610861381138717138770
   PubMed Web of Science ®Google Scholar
• EisingerSHFiscellaJBonfiglioTMeldrumSFiscellaKOpen-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomataEur J Obstet Gynecol Reprod Biol2009146221521819586708
   PubMed Web of Science ®Google Scholar
• BagariaMSunejaAVaidNBGuleriaKMishraKLow-dose mifepristone in treatment of uterine leiomyoma: a randomized double-blind placebo-controlled clinical trialAust N Z J Obstet Gynaecol2009491778319281585
   PubMed Web of Science ®Google Scholar
• EngmanMGranbergSWilliamsARMifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trialHum Reprod20092481870187919389793
   PubMed Web of Science ®Google Scholar
• MukherjeeSChakrabortySA study evaluating the effect of mifepristone (RU-486) for the treatment of leiomyomata uteriNiger Med J201152315015222083454
   PubMedGoogle Scholar
• SethSGoelNSinghEMathurASGuptaGEffect of mifepristone (25 mg) in treatment of uterine myoma in perimenopausal womanJ Midlife Health201341222623833529
   PubMedGoogle Scholar
• KulshresthaVKriplaniAAgarwalNLow dose mifepristone in medical management of uterine leiomyoma – an experience from a tertiary care hospital from north IndiaIndian J Med Res201313761154116223852296
   PubMed Web of Science ®Google Scholar
• FengCMeldrumSFiscellaKImproved quality of life is partly explained by fewer symptoms after treatment of fibroids with mifepristoneInt J Gynaecol Obstet2010109212112420132932
   PubMed Web of Science ®Google Scholar
• TristanMOrozcoLJSteedAMifepristone for uterine fibroidsCochrane Database Syst Rev20128CD007687
   PubMed Web of Science ®Google Scholar
• ShenQHuaYJiangWEffects of mifepristone on uterine leiomyoma in premenopausal women: a meta-analysisFertil Steril2013100661722–1726.e11722–1726.e10
   Google Scholar
• CarbonellJLAcostaRPérezYSafety and effectiveness of different dosage of mifepristone for the treatment of uterine fibroids: a double-blind randomized clinical trialInt J Womens Health2013511512423658500
   PubMedGoogle Scholar
• EsteveJLAcostaRPérezYMifepristone versus placebo to treat uterine myoma: a double-blind, randomized clinical trialInt J Womens Health2013536136923843709
   PubMedGoogle Scholar
• KapurAAngomchanuRDeyMEfficacy of use of long-term, low-dose mifepristone for the treatment of fibroidsJ Obstet Gynecol India201666Suppl 149449827651652
   PubMedGoogle Scholar
• AroraDChawlaJKocharSPSSharmaJCA randomized control trial to assess efficacy of mifepristone in medical management of uterine fibroidMed J Armed Forces India201773326727328790785
   PubMedGoogle Scholar
• YerushalmiGMGilboaYJakobson-SettonAVaginal mifepristone for the treatment of symptomatic uterine leiomyomata: an open-label studyFertil Steril2014101249650024220703
   PubMed Web of Science ®Google Scholar
• YangYZhengSZhangZEffects of mifepristone on gene expression of epidermal growth factor in human uterine leiomyomaZhonghua Fu Chan Ke Za Zhi1998331383910682457
   PubMedGoogle Scholar
• SunMZhuGZhouLEffect of mifepristone on the expression of progesterone receptor messenger RNA and protein in uterine leiomyomataZhonghua Fu Chan Ke Za Zhi199833422723110682471
   PubMedGoogle Scholar
• EngmanMVargheseSLagerstedt RobinsonKGSTM1 gene expression correlates to leiomyoma volume regression in response to mifepristone treatmentPLoS One2013812e8011424324590
   PubMed Web of Science ®Google Scholar
• DemannoDElgerWGargRAsoprisnil (J867): a selective progesterone receptor modulator for gynecological therapySteroids20036810–131019103214667995
   PubMed Web of Science ®Google Scholar
• ChwaliszKPerezMCDemannoDWinkelCSchubertGElgerWSelective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosisEndocr Rev200526342343815857972
   PubMed Web of Science ®Google Scholar
• ChwaliszKPerezMCWinkelCAsoprisnil, a selective progesterone receptor modulator (SPRM), for the management of symptomatic leiomyomataBrosensIUterine Leiomyomata: Pathogenesis and ManagementLondon and New YorkTaylor & Francis2006301311
   Google Scholar
• ChenWOharaNWangJA novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cellsJ Clin Endocrinol Metab20069141296130416464945
   PubMed Web of Science ®Google Scholar
• WangJOharaNWangZA novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cellsHum Reprod20062171869187716613890
   PubMed Web of Science ®Google Scholar
• SasakiHOharaNXuQA novel selective progesterone receptor modulator asoprisnil activates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated signaling pathway in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cellsJ Clin Endocrinol Metab200792261662317105846
   PubMed Web of Science ®Google Scholar
• XuQOharaNLiuJSelective progesterone receptor modulator asoprisnil induces endoplasmic reticulum stress in cultured human uterine leiomyoma cellsAm J Physiol Endocrinol Metab20072934E1002E101117652152
   PubMed Web of Science ®Google Scholar
• MorikawaAOharaNQinXSelective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducerHum Reprod200823494495118281245
   PubMed Web of Science ®Google Scholar
• WilkensJWilliamsARChwaliszKHanCCameronITCritchleyHOEffect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTENHum Reprod20092451036104419176543
   PubMed Web of Science ®Google Scholar
• WilkensJChwaliszKHanCEffects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomyJ Clin Endocrinol Metab200893124664467118765509
   PubMed Web of Science ®Google Scholar
• WilkensJMaleVGhazalPUterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnilJ Immunol201319152226223523913972
   PubMed Web of Science ®Google Scholar
• AttardiBJBurgensonJHildSAReelJRBlyeRPCDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914Mol Cell Endocrinol20021881–211112311911951
   PubMed Web of Science ®Google Scholar
• LuoXYinPCoonVJSChengYHWiehleRDBulunSEThe selective progesterone receptor modulator CDB4124 inhibits proliferation and induces apoptosis in uterine leiomyoma cellsFertil Steril20109382668267320056218
   PubMed Web of Science ®Google Scholar
• RoederHJayesFFengLLeppertPCCDB-4124 does not cause apoptosis in cultured fibroid cellsReprod Sci201118985085721422050
   PubMed Web of Science ®Google Scholar
• MacdonaldGUS FDA reaffirms hold on oral Proellex trials prompting Repros rethink (19-July-2017) https://www.in-pharmatechnologist.com/Article/2017/07/19/US-FDA-reaffirms-hold-on-oral-Proellex-trials-prompting-Repros-rethinkAccessed October 18, 2018
   Google Scholar
• RaoPNAcostaCKBahrMLA practical large-scale synthesis of 17alpha-acetoxy-11beta-(4-N, N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione (CDB-2914)Steroids200065739540010899539
   PubMed Web of Science ®Google Scholar
• GainerEEUlmannAPharmacologic properties of CDB(VA)-2914. A promising candidate for use in contraception as well as treatment of uterine fibroids and endometriosisSteroids2003681005101114667993
   PubMed Web of Science ®Google Scholar
• BlitheDLNiemanLKBlyeRPStrattonPPassaroMDevelopment of the selective progesterone receptor modulator CDB-2914 for clinical indicationsSteroids20036810–131013101714667994
   PubMed Web of Science ®Google Scholar
• XuQTakekidaSOharaNProgesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5′-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cellsJ Clin Endocrinol Metab200590295396115572421
   PubMed Web of Science ®Google Scholar
• XuQOharaNChenWProgesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cellsHum Reprod20062192408241616720624
   PubMed Web of Science ®Google Scholar
• MaruoTOharaNMatsuoHEffects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomasContraception2007756 SupplS99S10317531625
   PubMed Web of Science ®Google Scholar
• HorakPMaraMDundrPEffect of a selective progesterone receptor modulator on induction of apoptosis in uterine fibroids in vivoInt J Endocrinol2012201243617422844281
   PubMed Web of Science ®Google Scholar
• PohlOZobristRHGottelandJPThe clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroidsReprod Sci201522447648325228633
   PubMed Web of Science ®Google Scholar
• CiarmelaPCarrarelliPIslamMSUlipristal acetate modulates the expression and functions of activin A in leiomyoma cellsReprod Sci20142191120112525001022
   PubMed Web of Science ®Google Scholar
• LevensEDPotlog-NahariCArmstrongAYCDB-2914 for uterine leiomyomata treatment: a randomized controlled trialObstet Gynecol200811151129113618448745
   PubMed Web of Science ®Google Scholar
• NiemanLKBlockerWNanselTEfficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb studyFertil Steril201195276777221055739
   PubMed Web of Science ®Google Scholar
• PowellMDuttaDEsmya and the PEARL studies: a reviewWomens Health201612544548
   Google Scholar
• DonnezJTatarchukTFBouchardPUlipristal acetate versus placebo for fibroid treatment before surgeryN Engl J Med2012366540942022296075
   PubMed Web of Science ®Google Scholar
• DonnezJTomaszewskiJVázquezFUlipristal acetate versus leuprolide acetate for uterine fibroidsN Engl J Med2012366542143222296076
   PubMed Web of Science ®Google Scholar
• DonnezJVázquezFTomaszewskiJLong-term treatment of uterine fibroids with ulipristal acetateFertil Steril201410161565157324630081
   PubMed Web of Science ®Google Scholar
• DonnezJHudecekRDonnezOEfficacy and safety of repeated use of ulipristal acetate in uterine fibroidsFertil Steril2015103251952725542821
   PubMed Web of Science ®Google Scholar
• KalampokasTKamathMBoutasIKalampokasEUlipristal acetate for uterine fibroids: a systematic review and meta-analysisGynecol Endocrinol2016322919626572056
   PubMed Web of Science ®Google Scholar
• DonnezJDonnezOMatuleDLong-term medical management of uterine fibroids with ulipristal acetateFertil Steril2016105116517326477496
   PubMed Web of Science ®Google Scholar
• FauserBCDonnezJBouchardPSafety after extended repeated use of ulipristal acetate for uterine fibroidsPLoS One2017123e017352328267814
   PubMed Web of Science ®Google Scholar
• PourcelotAGCapmasPFernandezHPlace of ulipristal acetate in the management of uterine fibroids: preoperative treatment or sequential treatment?J Gynecol Obstet Hum Reprod201746324925428403922
   PubMed Web of Science ®Google Scholar
• European Medicine AgencyEsmya: new measures to minimise risk of rare but serious liver injury Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Esmya/human_referral_prac_000070.jsp&mid=WC0b01ac05805c516fAccessed May 13, 2018
   Google Scholar
• European Medicine Agency Committee for Medicinal Products for Human Use (CHMP) EMA/CHMP/417636/2018 Ulipristal Acetate Geden RichterAccessed on May 30, 2018
   Google Scholar
• WilliamsARCritchleyHOOseiJThe effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomataHum Reprod20072261696170417339234
   PubMed Web of Science ®Google Scholar
• MutterGLBergeronCDeligdischLThe spectrum of endometrial pathology induced by progesterone receptor modulatorsMod Pathol200821559159818246050
   PubMed Web of Science ®Google Scholar
• SpitzIMClinical utility of progesterone receptor modulators and their effect on the endometriumCurr Opin Obstet Gynecol200921431832419602929
   PubMed Web of Science ®Google Scholar
• FraserISLow-dose mifepristone: effects on the endometriumAust N Z J Obstet Gynaecol200949778319281585
   PubMed Web of Science ®Google Scholar
• FiscellaJBonfiglioTWintersPEisingerSHFiscellaKDistinguishing features of endometrial pathology after exposure to the progesterone receptor modulator mifepristoneHum Pathol201142794795321315422
   PubMed Web of Science ®Google Scholar
• HelmestamMLindgrenKEStavreus-EversAOlovssonMMifepristone-exposured human endometrial endothelial cells in vitroReprod Sci201421340841423885098
   PubMed Web of Science ®Google Scholar
• IoffeOBZainoRJMutterGLEndometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulatorMod Pathol200922345045919136935
   PubMed Web of Science ®Google Scholar
• YoshidaSOharaNXuQCell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growthSemin Reprod Med201028326027320414849
   PubMed Web of Science ®Google Scholar
• Chabbert-BuffetNPintiaux-KairisABouchardPVA2914 Study GroupEffects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trialJ Clin Endocrinol Metab20079293582358917579200
   PubMed Web of Science ®Google Scholar
• RavetSMunautCBlacherSPersistence of an intact endometrial matrix and vessels structure in women exposed to VA-2914, a selective progesterone receptor modulatorJ Clin Endocrinol Metab200893114525453118728171
   PubMed Web of Science ®Google Scholar
• WeiQLevensEDStefanssonLNiemanLKIndian Hedgehog and its targets in human endometrium: menstrual cycle expression and response to CDB-2914J Clin Endocrinol Metab201095125330533720881264
   PubMed Web of Science ®Google Scholar
• BrennerRMSlaydenODNathATsongYYSitruk-WareRIntrauterine administration of CDB-2914 (Ulipristal) suppresses the endometrium of rhesus macaquesContraception201081433634220227552
   PubMed Web of Science ®Google Scholar
• WilliamsARBergeronCBarlowDHFerenczyAEndometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetateInt J Gynecol Pathol201231655656923018219
   PubMed Web of Science ®Google Scholar
• DonnezJDonnezODolmansMMSafety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetateExpert Opin Drug Saf201615121679168627740868
   PubMed Web of Science ®Google Scholar
• de MillianoIvan HattumDKetJCFHuirneJAFHehenkampWJKEndometrial changes during ulipristal acetate use: a systematic reviewEur J Obstet Gynecol Reprod Biol2017214566428482329
   PubMed Web of Science ®Google Scholar
• BenagianoGPrimieroFMThe potential use of antiprogestins in gynaecological disordersMottaMSerioMSex Hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical AspectsAmsterdamElsevier Science1994391399
   Google Scholar
• IslamMSProticOGiannubiloSRUterine leiomyoma: available medical treatments and new possible therapeutic optionsJ Clin Endocrinol Metab201398392193423393173
   PubMed Web of Science ®Google Scholar
• WagenfeldASaundersPTWhitakerLCritchleyHOSelective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapiesExpert Opin Ther Targets20162091045105427138351
   PubMed Web of Science ®Google Scholar
• MurjiAWhitakerLChowTLSobelMLSelective progesterone receptor modulators (SPRMs) for uterine fibroidsCochrane Database Syst Rev20174CD01077028444736
   PubMed Web of Science ®Google Scholar
• DonnezJHervais VivancosBKudelaMAudebertAJadoulPA randomized, placebo-controlled, dose-ranging trial comparing fulvestrant with goserelin in premenopausal patients with uterine fibroids awaiting hysterectomyFertil Steril20037961380138912798886
   PubMed Web of Science ®Google Scholar
• LethabyAPuscasiuLVollenhovenBPreoperative medical therapy before surgery for uterine fibroidsCochrane Database Syst Rev201711CD000547art. no. CD00054729139105
   PubMed Web of Science ®Google Scholar